Mind Medicine Gets UK's Innovation Passport Designation for Investigational Anxiety Disorder Treatment

MT Newswires Live12-06

Mind Medicine (MNMD) said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently in clinical development for the treatment of generalized anxiety disorder.

The designation allows access to tools to support the design, development, and approvals process in the UK, and provides opportunities for enhanced regulatory and other stakeholder input, the biopharmaceutical company said.

The passport is considered an "entry point" to the Innovative Licensing and Access Pathway, a program that seeks to speed up patients' access to new medicines, the company said.

Shares of the Mind Medicine fell 3.6% in recent Thursday trading.

Price: 7.21, Change: -0.27, Percent Change: -3.61

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489467616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 01:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489467616","market":"nz","top_or_hot":-1,"title":"Mind Medicine Gets UK's Innovation Passport Designation for Investigational Anxiety Disorder Treatment","media":"MT Newswires Live","content":"<html><body><p> Mind Medicine (MNMD) said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently in clinical development for the treatment of generalized anxiety disorder.</p><p>The designation allows access to tools to support the design, development, and approvals process in the UK, and provides opportunities for enhanced regulatory and other stakeholder input, the biopharmaceutical company said.</p><p>The passport is considered an \"entry point\" to the Innovative Licensing and Access Pathway, a program that seeks to speed up patients' access to new medicines, the company said.</p><p>Shares of the Mind Medicine fell 3.6% in recent Thursday trading.</p><p>Price: 7.21, Change: -0.27, Percent Change: -3.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mind Medicine Gets UK's Innovation Passport Designation for Investigational Anxiety Disorder Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMind Medicine Gets UK's Innovation Passport Designation for Investigational Anxiety Disorder Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mind Medicine (MNMD) said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNMD","symbol_name":"Mind Medicine (MindMed) Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489467616","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489467616","pubTimestamp":1733418032,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mind Medicine  said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently in clinical development for the treatment of generalized anxiety disorder.The designation allows access to tools to support the design, development, and approvals process in the UK, and provides opportunities for enhanced regulatory and other stakeholder input, the biopharmaceutical company said.The passport is considered an \"entry point\" to the Innovative Licensing and Access Pathway, a program that seeks to speed up patients' access to new medicines, the company said.Shares of the Mind Medicine fell 3.6% in recent Thursday trading.Price: 7.21, Change: -0.27, Percent Change: -3.61","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNMD":"Mind Medicine (MindMed) Inc.","BK4007":"制药","BK4547":"WSB热门概念"},"translate_title":"Mind Medicine获得英国研究性焦虑症治疗创新护照指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"Mind Medicine (MNMD) said Thursday the UK's Medicines and Healthcare Products Regulatory Agency granted an Innovation Passport designation for its MM120 orally disintegrated table, which is currently in clinical development for the treatment of generalized anxiety disorder.The designation allows access to tools to support the design, development, and approvals process in the UK, and provides opportunities for enhanced regulatory and other stakeholder input, the biopharmaceutical company said.The passport is considered an \"entry point\" to the Innovative Licensing and Access Pathway, a program that seeks to speed up patients' access to new medicines, the company said.Shares of the Mind Medicine fell 3.6% in recent Thursday trading.Price: 7.21, Change: -0.27, Percent Change: -3.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489467616"}